Mavenclad
Mavenclad ingredients
| Active ingredient | Strength |
|---|---|
| Cladribine | 10 mg/1 |
What Mavenclad is used for
The FDA lists the approved uses on the official label (below). In the EU, cladribine is approved as Mavenclad for:
Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Mavenclad
- Generic name
- Cladribine
- Made by
- EMD Serono, Inc.
- Forms
- Tablet
- Given
- Oral
- Drug class
- Purine Antimetabolite
- FDA approval
- New drug application (NDA) NDA022561
- On the US market since
- 2019
Official information
- Mavenclad prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Cladribine)
In India
- Cladribine: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Mavenclad?
Mavenclad (Cladribine) is a cancer medicine made by EMD Serono, Inc., approved by the US FDA.
What are the ingredients of Mavenclad?
Mavenclad contains Cladribine (10 mg/1).
Is Mavenclad approved in Europe?
The same active substance is approved in the EU as Mavenclad, Litak.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA